Post-Hoc Live: Is biotech’s relationship with the FDA at a breaking point? news2026-02-11T14:21:30+00:00February 11th, 2026|Endpoints News|
Moderna accuses FDA of shifting standard as agency refuses flu shot reviewnews2026-02-10T23:00:09+00:00February 10th, 2026|Endpoints News|
NIH stops low-dose Xarelto arm of large stroke study due to safety concernsnews2026-02-10T19:55:14+00:00February 10th, 2026|Endpoints News|
FDA rejects Regenxbio’s Hunter syndrome gene therapynews2026-02-09T21:15:23+00:00February 9th, 2026|Endpoints News|
With scant data, RFK Jr. credits Trump for higher European drug pricesnews2026-02-09T20:44:29+00:00February 9th, 2026|Endpoints News|
Orphan drug tweak in US spending bill will make life easier for the FDAnews2026-02-06T19:10:15+00:00February 6th, 2026|Endpoints News|
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trialnews2026-02-05T17:15:12+00:00February 5th, 2026|Endpoints News|
Rare pediatric PRV program reauthorized until 2029 via government funding lawnews2026-02-04T18:27:40+00:00February 4th, 2026|Endpoints News|
FDA seeks withdrawal of Amgen’s Tavneos, but company says it won’t pull drugnews2026-02-04T00:48:19+00:00February 4th, 2026|Endpoints News|
AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelonews2026-02-03T12:03:52+00:00February 3rd, 2026|Endpoints News|
